Anzeige
Mehr »
Login
Samstag, 04.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
InnoCan Pharma: Multi-Milliarden-Wert in diesem Pennystock?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
15 Leser
Artikel bewerten:
(0)

Bell's Palsy - Forecast in 15 Major Markets 2017-2027 - Overview of Risk Factors, Disease Diagnosis & Prognosis - Research and Markets

DUBLIN, Feb. 9, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Bell's Palsy Forecast in 15 Major Markets 2017-2027" report to their offering.

Bell's palsy, also known as idiopathic facial nerve palsy, is a weakness of the muscles on one side of the face caused by the compression of the facial/cranial nerve, with no known underlying pathological cause. Such a condition typically manifests in a unilateral paralysis of the face. In rare cases, both sides of the face can be affected. Bell's palsy is characterized by its rapid onset, reaching clinical peak within 72 hours. Most patients fully recover from Bell's palsy.

This report provides the current incident population for Bell's palsy across 15 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, China, Turkey, Mexico, Denmark, Egypt and South Korea) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Main symptoms and co-morbidities for Bell's palsy include:

  • Rapid onset of mild weakness to total paralysis on one side of the face
  • Facial droop
  • Drooling
  • Increased sensitivity to sound on the affected side
  • Headache
  • Synkinesis (involuntary facial movement)
  • Decrease in taste sensations
  • Pain around the jaw
  • Pain behind the ear on the affected side
  • Change in volume of tears/saliva that the individual may produce

Reasons to Buy:

  • Able to quantify patient populations in global Bell's palsy market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the incidence of the subdivided types of Bell's palsy and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Bell's palsy incident population.
  • Identify sub-populations within Bell's palsy which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Bell's palsy patients.

Key Topics Covered:

1. Introduction

2. Cause of the Disease

3. Risk Factors & Prevention

4. Diagnosis of the Disease

5. Variation by Geography/Ethnicity

6. Disease Prognosis & Clinical Course

7. Key comorbid conditions/Features associated with the disease

8. Methodology for quantification of patient numbers

9. Top-line incidence for Bell's palsy

10. Features of Bell's palsy patients

11. Recurrence of Bell's palsy

12. Sequelae and features of Bell's palsy patients

13. Co-morbidities of patients with Bell's palsy

14. Abbreviations used in the report

15. Patient-Based Offering

16. Online Pricing Data and Platforms

17. References

18. Appendix

For more information about this report visit http://www.researchandmarkets.com/research/2kwqrl/bells_palsy

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2017 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.